1. Scrip

Tesaro's Zejula Expansion Includes Keytruda Combo, Lung Cancer

 
• By Jessica Merrill

The company, encouraged by positive Phase I data from a trial testing the PARP inhibitor niraparib in combination with Merck's PD-1 inhibitor Keytruda in recurrent ovarian cancer, plans to initiate a larger trial by the end of the year or early in 2018.

Cancer cells

Tesaro Inc. is moving forward with ambitions to expand the poly ADP-ribose polymerase (PARP) inhibitor Zejula (niraparib) to more indications beyond recurrent ovarian cancer, including as a front-line treatment for ovarian cancer, in combination with the immunotherapy Keytruda (pembrolizumab), in triple-negative breast cancer and lung cancer.

Management outlined the expansion strategy and some encouraging early data during an investor briefing at the American Society of Clinical Oncology meeting in Chicago on June 3.

More from New Products

More from Scrip

Sweden’s Hansa Slims Down Ahead of Key Readouts

 
• By Kevin Grogan

New CEO Renée Aguiar-Lucander is marking her mark.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Novo Nordisk’s CEO forced out; quantifying biopharma’s contribution to the US economy; a history of MASH deals; lift for AstraZeneca’s asthma ambitions; and major Japanese firms see US revenue growth.

Ascentage Broadens Horizons As Pipeline Shows Renewed Promise

 
• By Xu Hu

Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.